68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
About this study
68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
- Condition
- Prostate Cancer (Adenocarcinoma)
- Tested
- 68Ga-PSMA-11
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Who can join
- Age
- 18 to 80 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Maximum age: 80 years
- Eligible sex: Male
- Study condition: Prostate Cancer (Adenocarcinoma)
- Biopsy-confirmed adenocarcinoma of the prostate.
- No anti-tumor treatment received prior to the PET imaging.
- Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.
- Radical prostatectomy scheduled within 28 days after PET imaging
Exclusion 2
- Patients with other malignant tumors
- Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.
Where
1 site, 1 recruiting
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Contact
-
Weibing Miao, MD
86-0591-87981618 miaoweibing@126.com
-
Guochang Wang, MD
86-0591-87981619 guochang1007@163.com
Potential match only. Final eligibility is determined by the study team.